Akèy › Kansè ovè › Distrik Columbia › Washington
Etid klinik pou Kansè ovè nan Washington, DC
23 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Washington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Ap rekriteFaz 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Ap rekriteFaz 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Ap rekriteEtid obsèvasyon
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Ap rekriteEtid obsèvasyon
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Ap rekriteFaz 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Holy Cross Hospital /ID# 275872, Silver Spring · 7 mi lwen
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Ap rekriteFaz 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Ap rekriteFaz 3
- MedStar Washington Hospital Center ( Site 0026), Washington D.C.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Georgetown University Medical Center, Washington D.C.
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 3
- Holy Cross Hospital, Silver Spring · 7 mi lwen
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 2
- Medstar Georgetown University Hospital, Washington D.C.
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Ap rekriteFaz 3
- Holy Cross Hospital, Silver Spring · 7 mi lwen
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Children's National Medical Center, Washington D.C.
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ap rekriteFaz 1
- Normunity Investigational Site, Washington D.C.
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Ap rekriteFaz 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA11-0, Bethesda · 7 mi lwen
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Ap rekriteFaz 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Cancer Support Community Research & Training Institute, Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Silver Spring · 7 mi lwen
- Massive Bio SYNERGY-AI site, Bethesda · 7 mi lwen
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Ap rekriteVolontè an sante akeyi
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Ap rekriteFaz 1
- Holy Cross Hospital, Silver Spring · 7 mi lwen
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan Washington
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil55 etid
- Kansè nan tete46 etid
- Kansè Metastatik43 etid
- Kansè poumon41 etid
- Kansè pwostat38 etid
- Obèsite33 etid
- Kansè kolorektal29 etid
- Maladi kadyovaskilè28 etid
- Kansè vejik26 etid
- Leksemi mieloïd egi24 etid
- Limfom23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.